Management of Type IIb Dyslipidemia
Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardio...
Gespeichert in:
| Veröffentlicht in: | Journal of Atherosclerosis and Thrombosis 2012, Vol.19(2), pp.105-114 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 2 |
| container_start_page | 105 |
| container_title | Journal of Atherosclerosis and Thrombosis |
| container_volume | 19 |
| creator | Arai, Hidenori Ishibashi, Shun Bujo, Hideaki Hayashi, Toshio Yokoyama, Shinji Oikawa, Shinichi Kobayashi, Junji Shirai, Kohji Ota, Takao Yamashita, Shizuya Gotoda, Takanari Harada-Shiba, Mariko Sone, Hirohito Eto, Masaaki Suzuki, Hiroaki Yamada, Nobuhiro |
| description | Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia. |
| doi_str_mv | 10.5551/jat.10447 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_925718372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>925718372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-94e164e45997628c4c9a232d62de7fc755b540bbfd4c9c98e15cb5777d143fa33</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EoqUw8AdQJAbEkOJnHE8IlVelIpYyW45zA6nywk6G_nvcpnS590jn0xk-hK4JngshyMPG9HOCOZcnaErSFMcslew0ZMZD5jKdoAvvNxgzJgQ9RxNKCVOc0Sm6_TCN-YYamj5qi2i97SBaLrPoeeursitzqEtzic4KU3m4OvwZ-np9WS_e49Xn23LxtIqtSJI-VhxIwoELpWRCU8utMpTRPKE5yMJKITLBcZYVeWisSoEImwkpZU44KwxjM3Q37nau_R3A97ouvYWqMg20g9eKCklSJmkg70fSutZ7B4XuXFkbt9UE650SHZTovZLA3hxWh6yG_Ej-OwjA4whsfB9UHAHj-tJWME4pTXdnP3ls7I9xGhr2B4UJcJs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>925718372</pqid></control><display><type>article</type><title>Management of Type IIb Dyslipidemia</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Arai, Hidenori ; Ishibashi, Shun ; Bujo, Hideaki ; Hayashi, Toshio ; Yokoyama, Shinji ; Oikawa, Shinichi ; Kobayashi, Junji ; Shirai, Kohji ; Ota, Takao ; Yamashita, Shizuya ; Gotoda, Takanari ; Harada-Shiba, Mariko ; Sone, Hirohito ; Eto, Masaaki ; Suzuki, Hiroaki ; Yamada, Nobuhiro</creator><creatorcontrib>Arai, Hidenori ; Ishibashi, Shun ; Bujo, Hideaki ; Hayashi, Toshio ; Yokoyama, Shinji ; Oikawa, Shinichi ; Kobayashi, Junji ; Shirai, Kohji ; Ota, Takao ; Yamashita, Shizuya ; Gotoda, Takanari ; Harada-Shiba, Mariko ; Sone, Hirohito ; Eto, Masaaki ; Suzuki, Hiroaki ; Yamada, Nobuhiro ; Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan</creatorcontrib><description>Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia.</description><identifier>ISSN: 1340-3478</identifier><identifier>EISSN: 1880-3873</identifier><identifier>DOI: 10.5551/jat.10447</identifier><identifier>PMID: 22139432</identifier><language>eng</language><publisher>Japan: Japan Atherosclerosis Society</publisher><subject>Atherogenic dyslipidemia ; Cardiovascular disease ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention & control ; Diabetes ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - prevention & control ; Disease Management ; Dyslipidemias - complications ; Dyslipidemias - prevention & control ; Humans ; Lifestyle modification ; Metabolic syndrome ; Metabolic Syndrome - etiology ; Metabolic Syndrome - prevention & control</subject><ispartof>Journal of Atherosclerosis and Thrombosis, 2012, Vol.19(2), pp.105-114</ispartof><rights>2012 Japan Atherosclerosis Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-94e164e45997628c4c9a232d62de7fc755b540bbfd4c9c98e15cb5777d143fa33</citedby><cites>FETCH-LOGICAL-c566t-94e164e45997628c4c9a232d62de7fc755b540bbfd4c9c98e15cb5777d143fa33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22139432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arai, Hidenori</creatorcontrib><creatorcontrib>Ishibashi, Shun</creatorcontrib><creatorcontrib>Bujo, Hideaki</creatorcontrib><creatorcontrib>Hayashi, Toshio</creatorcontrib><creatorcontrib>Yokoyama, Shinji</creatorcontrib><creatorcontrib>Oikawa, Shinichi</creatorcontrib><creatorcontrib>Kobayashi, Junji</creatorcontrib><creatorcontrib>Shirai, Kohji</creatorcontrib><creatorcontrib>Ota, Takao</creatorcontrib><creatorcontrib>Yamashita, Shizuya</creatorcontrib><creatorcontrib>Gotoda, Takanari</creatorcontrib><creatorcontrib>Harada-Shiba, Mariko</creatorcontrib><creatorcontrib>Sone, Hirohito</creatorcontrib><creatorcontrib>Eto, Masaaki</creatorcontrib><creatorcontrib>Suzuki, Hiroaki</creatorcontrib><creatorcontrib>Yamada, Nobuhiro</creatorcontrib><creatorcontrib>Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan</creatorcontrib><title>Management of Type IIb Dyslipidemia</title><title>Journal of Atherosclerosis and Thrombosis</title><addtitle>JAT</addtitle><description>Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia.</description><subject>Atherogenic dyslipidemia</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - prevention & control</subject><subject>Disease Management</subject><subject>Dyslipidemias - complications</subject><subject>Dyslipidemias - prevention & control</subject><subject>Humans</subject><subject>Lifestyle modification</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - etiology</subject><subject>Metabolic Syndrome - prevention & control</subject><issn>1340-3478</issn><issn>1880-3873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EoqUw8AdQJAbEkOJnHE8IlVelIpYyW45zA6nywk6G_nvcpnS590jn0xk-hK4JngshyMPG9HOCOZcnaErSFMcslew0ZMZD5jKdoAvvNxgzJgQ9RxNKCVOc0Sm6_TCN-YYamj5qi2i97SBaLrPoeeursitzqEtzic4KU3m4OvwZ-np9WS_e49Xn23LxtIqtSJI-VhxIwoELpWRCU8utMpTRPKE5yMJKITLBcZYVeWisSoEImwkpZU44KwxjM3Q37nau_R3A97ouvYWqMg20g9eKCklSJmkg70fSutZ7B4XuXFkbt9UE650SHZTovZLA3hxWh6yG_Ej-OwjA4whsfB9UHAHj-tJWME4pTXdnP3ls7I9xGhr2B4UJcJs</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Arai, Hidenori</creator><creator>Ishibashi, Shun</creator><creator>Bujo, Hideaki</creator><creator>Hayashi, Toshio</creator><creator>Yokoyama, Shinji</creator><creator>Oikawa, Shinichi</creator><creator>Kobayashi, Junji</creator><creator>Shirai, Kohji</creator><creator>Ota, Takao</creator><creator>Yamashita, Shizuya</creator><creator>Gotoda, Takanari</creator><creator>Harada-Shiba, Mariko</creator><creator>Sone, Hirohito</creator><creator>Eto, Masaaki</creator><creator>Suzuki, Hiroaki</creator><creator>Yamada, Nobuhiro</creator><general>Japan Atherosclerosis Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Management of Type IIb Dyslipidemia</title><author>Arai, Hidenori ; Ishibashi, Shun ; Bujo, Hideaki ; Hayashi, Toshio ; Yokoyama, Shinji ; Oikawa, Shinichi ; Kobayashi, Junji ; Shirai, Kohji ; Ota, Takao ; Yamashita, Shizuya ; Gotoda, Takanari ; Harada-Shiba, Mariko ; Sone, Hirohito ; Eto, Masaaki ; Suzuki, Hiroaki ; Yamada, Nobuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-94e164e45997628c4c9a232d62de7fc755b540bbfd4c9c98e15cb5777d143fa33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Atherogenic dyslipidemia</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - prevention & control</topic><topic>Disease Management</topic><topic>Dyslipidemias - complications</topic><topic>Dyslipidemias - prevention & control</topic><topic>Humans</topic><topic>Lifestyle modification</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - etiology</topic><topic>Metabolic Syndrome - prevention & control</topic><toplevel>online_resources</toplevel><creatorcontrib>Arai, Hidenori</creatorcontrib><creatorcontrib>Ishibashi, Shun</creatorcontrib><creatorcontrib>Bujo, Hideaki</creatorcontrib><creatorcontrib>Hayashi, Toshio</creatorcontrib><creatorcontrib>Yokoyama, Shinji</creatorcontrib><creatorcontrib>Oikawa, Shinichi</creatorcontrib><creatorcontrib>Kobayashi, Junji</creatorcontrib><creatorcontrib>Shirai, Kohji</creatorcontrib><creatorcontrib>Ota, Takao</creatorcontrib><creatorcontrib>Yamashita, Shizuya</creatorcontrib><creatorcontrib>Gotoda, Takanari</creatorcontrib><creatorcontrib>Harada-Shiba, Mariko</creatorcontrib><creatorcontrib>Sone, Hirohito</creatorcontrib><creatorcontrib>Eto, Masaaki</creatorcontrib><creatorcontrib>Suzuki, Hiroaki</creatorcontrib><creatorcontrib>Yamada, Nobuhiro</creatorcontrib><creatorcontrib>Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arai, Hidenori</au><au>Ishibashi, Shun</au><au>Bujo, Hideaki</au><au>Hayashi, Toshio</au><au>Yokoyama, Shinji</au><au>Oikawa, Shinichi</au><au>Kobayashi, Junji</au><au>Shirai, Kohji</au><au>Ota, Takao</au><au>Yamashita, Shizuya</au><au>Gotoda, Takanari</au><au>Harada-Shiba, Mariko</au><au>Sone, Hirohito</au><au>Eto, Masaaki</au><au>Suzuki, Hiroaki</au><au>Yamada, Nobuhiro</au><aucorp>Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Type IIb Dyslipidemia</atitle><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle><addtitle>JAT</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>19</volume><issue>2</issue><spage>105</spage><epage>114</epage><pages>105-114</pages><issn>1340-3478</issn><eissn>1880-3873</eissn><abstract>Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia.</abstract><cop>Japan</cop><pub>Japan Atherosclerosis Society</pub><pmid>22139432</pmid><doi>10.5551/jat.10447</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-3478 |
| ispartof | Journal of Atherosclerosis and Thrombosis, 2012, Vol.19(2), pp.105-114 |
| issn | 1340-3478 1880-3873 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_925718372 |
| source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Atherogenic dyslipidemia Cardiovascular disease Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Diabetes Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - prevention & control Disease Management Dyslipidemias - complications Dyslipidemias - prevention & control Humans Lifestyle modification Metabolic syndrome Metabolic Syndrome - etiology Metabolic Syndrome - prevention & control |
| title | Management of Type IIb Dyslipidemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T09%3A25%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Type%20IIb%20Dyslipidemia&rft.jtitle=Journal%20of%20Atherosclerosis%20and%20Thrombosis&rft.au=Arai,%20Hidenori&rft.aucorp=Research%20Committee%20for%20Primary%20Hyperlipidemia,%20Research%20on%20Measures%20against%20Intractable%20Diseases%20by%20the%20Ministry%20of%20Health,%20Labour%20and%20Welfare%20in%20Japan&rft.date=2012-01-01&rft.volume=19&rft.issue=2&rft.spage=105&rft.epage=114&rft.pages=105-114&rft.issn=1340-3478&rft.eissn=1880-3873&rft_id=info:doi/10.5551/jat.10447&rft_dat=%3Cproquest_cross%3E925718372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=925718372&rft_id=info:pmid/22139432&rfr_iscdi=true |